Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38065
Title: | Two-year clinical outcomes after successful transcatheter aortic valve implantation with balloon-expandable versus self-expanding valves: A subanalysis of the GALILEO trial | Authors: | Okuno, Taishi Dangas, George D. Hengstenberg, Christian Sartori, Samantha Herrmann, Howard C. de Winter, Robert Gilard, Martine Tchetche, Didier Moellmann, Helge Makkar, Raj R. Baldus, Stephan De Backer, Ole Bendz, Bjorn Kini, Annapoorna von Lewinski, Dirk Mack, Michael Moreno, Raul Schaefer, Ulrich Woehrle, Jochen Seeger, Julia Snyder, Clayton Nicolas, Johny Tijssen, Jan G. P. Welsh, Robert C. VRANCKX, Pascal Valgimigli, Marco Mehran, Roxana Kapadia, Samir Sondergaard, Lars Windecker, Stephan |
Issue Date: | 2022 | Publisher: | WILEY | Source: | Catheterization and cardiovascular interventions, 100 (4), p. 636-645 | Abstract: | Background Midterm data comparing clinical outcomes after successful implantation of self-expanding and balloon-expandable transcatheter heart valves (THV) are limited. We aimed to compare 2-year outcomes after successful transcatheter aortic valve implantation (TAVI) with the Edwards balloon-expandable or the Medtronic self-expanding THV. Methods Two-year outcomes were analyzed according to the implanted THV in the GALILEO trial. Major adverse cardiac and cerebrovascular events (MACCE) was a composite of all-cause death or thromboembolic events including stroke, myocardial infarction, symptomatic valve thrombosis, systemic embolism, deep-vein thrombosis, or pulmonary embolism. Results Among 1644 patients recruited in 136 centers across 16 countries between 2015 and 2018, 499 received a self-expanding and 757 patients received a balloon-expandable THV. Patients treated with a self-expanding THV were more likely to be female, and had higher surgical risk, lower hemoglobin levels, and more frequent valve-in-valve procedures than those with a balloon-expandable THV. After multivariable adjustment, there were no significant differences in major clinical outcomes between self-expanding versus balloon-expandable THV: MACCE (17.0% vs. 13.4%, adjusted-hazard ratios [HR] 1.18, 95% confidence intervals [CI]: 0.82-1.69); all-cause death (11.4% vs. 9.3%, adjusted-HR 1.26; 95% CI: 0.78-2.05); cardiovascular death (8.5% vs. 4.0%, adjusted-HR 1.53; 95% CI: 0.82-2.86), any stroke (5.1% vs. 3.7%, adjusted-HR 0.86; 95% CI: 0.43-1.73); major or life-threatening bleeding (5.9% vs. 6.8%, adjusted-HR 0.93; 95% CI: 0.53-1.63). Clinical Trial Registration: . NCT02556203. Conclusions Two-year follow-up data from the GALILEO trial indicate that successful TAVI either with self-expanding or balloon-expandable THVs according to physician discretion did not show difference in rates of MACCE. | Notes: | Windecker, S (corresponding author), Bern Univ Hosp, Dept Cardiol, Inselspital, CH-3010 Bern, Switzerland. stephan.windecker@insel.ch |
Keywords: | aortic valve setenosis;balloon-expandable valve;GALILEO;major adverse cardiac and cerebrovascular events;self-expanding valve;successful implantation;transcatheter aortic valve implantation;transcatheter heart valve | Document URI: | http://hdl.handle.net/1942/38065 | ISSN: | 1522-1946 | e-ISSN: | 1522-726X | DOI: | 10.1002/ccd.30370 | ISI #: | 000847465300001 | Rights: | 2022 Wiley Periodicals LLC | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Two‐year clinical outcomes after successful transcatheter aortic valve implantation with balloon‐expandable versus self‐expanding valves_ A subanalysis of the GALILEO trial.pdf Restricted Access | Published version | 1.21 MB | Adobe PDF | View/Open Request a copy |
auteursversie.pdf | Peer-reviewed author version | 1.55 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.